Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
clinical trials
life sciences
national blog main
national top stories
new york blog main
new york top stories
4
×
new york
san diego blog main
san diego top stories
abbvie
bristol-myers squibb
drugs
intercept pharmaceuticals
nonalcoholic steatohepatitis
obeticholic acid
pfizer
san francisco blog main
san francisco top stories
4d molecular therapeutics
acne
acorda therapeutics
agenus
akcea therapeutics
allergan
ampyra
anylam pharmaceuticals
apokyn
apomorphine
astrazeneca
auris health
avexis
bayer
biomx
biotech
bladder cancer
boulder/denver blog main
boulder/denver top stories
broad institute of mit and harvard
What
approved
4
×
disease
4
×
drug
4
×
fda
fatty
known
liver
nash
new
patients
treatment
acorda
ago
akcea
alnylam
amyloidosis
attr
available
battle
bio
companies
cope
data
debilitating
digital
epidemic
episodes
frenzied
friday
genetic
gets
growing
help
horizon
intercept
late
led
looms
marketed
meant
Language
Current search:
disease
×
drug
×
" new york top stories "
×
approved
×
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
With New Data, Intercept On Track for First-Ever Approved NASH Drug
@xconomy.com
5 years ago
Acorda Gets FDA Nod For New Parkinson’s Drug, But Rival Looms